Table 3.
Literature review of surgery outcomes for ESOS.
| Reference | Year | Cases (metastases) | Median Age | OS rate | PFS rate (localized) |
|---|---|---|---|---|---|
| Lee JS13 | 1995 | 40 (0) | 50.7 (mean) | 5 y 37% | — |
| Ahmad SA15 | 2002 | 60 (22) | 55 | 5 y 46% (30 pts) | 5 y 46% |
| Torigoe T16 | 2007 | 20 (1) | 50 | 5 y 66% | — |
| Choi LE9 | 2014 | 53 (11) | 64 | 3 y 61% | 3 y 50% |
| Thampi S10 | 2014 | 256 (68) | 60.7 (mean) | 5 y 37% (47% for localized) | — |
| Berner K17 | 2015 | 37 (8)* | 68 | 5 y 16% | — |
| Fan Z8 | 2015 | 36 (0) | 59 (mean) | 5 y 53% | — |
| Longhi A14 | 2017 | 266 (55) | 57 | 5 y 47% (51.4% for localized) | 5 y 43% |
| Paludo J18 | 2017 | 43 (6) | 55 | 5 y 45% | 5 y 44% |
| Current study | 2018 | 22 (3) | 55.5 | 5 y 58% | 3 y 31% |
OS Overall survival; PFS progression-free-survival.
*Only 29 pts received surgery in Berner’s investigation.